210 related articles for article (PubMed ID: 34452691)
1. Toxicity testing and endocrine disrupting chemicals.
Vandenberg LN
Adv Pharmacol; 2021; 92():35-71. PubMed ID: 34452691
[TBL] [Abstract][Full Text] [Related]
2. Key learnings from performance of the U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 in vitro assays.
LeBaron MJ; Coady KK; O'Connor JC; Nabb DL; Markell LK; Snajdr S; Sue Marty M
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):23-42. PubMed ID: 24515815
[TBL] [Abstract][Full Text] [Related]
3. The use and acceptance of Other Scientifically Relevant Information (OSRI) in the U.S. Environmental Protection Agency (EPA) Endocrine Disruptor Screening Program.
Bishop PL; Willett CE
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):3-22. PubMed ID: 24151143
[TBL] [Abstract][Full Text] [Related]
4. A predictive data-driven framework for endocrine prioritization: a triazole fungicide case study.
Paul Friedman K; Papineni S; Marty MS; Yi KD; Goetz AK; Rasoulpour RJ; Kwiatkowski P; Wolf DC; Blacker AM; Peffer RC
Crit Rev Toxicol; 2016 Oct; 46(9):785-833. PubMed ID: 27347635
[TBL] [Abstract][Full Text] [Related]
5. Using in vitro high throughput screening assays to identify potential endocrine-disrupting chemicals.
Rotroff DM; Dix DJ; Houck KA; Knudsen TB; Martin MT; McLaurin KW; Reif DM; Crofton KM; Singh AV; Xia M; Huang R; Judson RS
Environ Health Perspect; 2013 Jan; 121(1):7-14. PubMed ID: 23052129
[TBL] [Abstract][Full Text] [Related]
6. Screening Chemicals for Estrogen Receptor Bioactivity Using a Computational Model.
Browne P; Judson RS; Casey WM; Kleinstreuer NC; Thomas RS
Environ Sci Technol; 2015 Jul; 49(14):8804-14. PubMed ID: 26066997
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of EPA's Tier 1 Endocrine Screening Battery and recommendations for improving the interpretation of screening results.
Borgert CJ; Mihaich EM; Quill TF; Marty MS; Levine SL; Becker RA
Regul Toxicol Pharmacol; 2011 Apr; 59(3):397-411. PubMed ID: 21251942
[TBL] [Abstract][Full Text] [Related]
8. Key lessons from performance of the U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 male and female pubertal assays.
Stump DG; O'Connor JC; Lewis JM; Marty MS
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):43-62. PubMed ID: 24510766
[TBL] [Abstract][Full Text] [Related]
9. Chlorpyrifos: weight of evidence evaluation of potential interaction with the estrogen, androgen, or thyroid pathways.
Juberg DR; Gehen SC; Coady KK; LeBaron MJ; Kramer VJ; Lu H; Marty MS
Regul Toxicol Pharmacol; 2013 Aug; 66(3):249-63. PubMed ID: 23524272
[TBL] [Abstract][Full Text] [Related]
10. Lessons learned, challenges, and opportunities: the U.S. Endocrine Disruptor Screening Program.
Juberg DR; Borghoff SJ; Becker RA; Casey W; Hartung T; Holsapple MP; Marty MS; Mihaich EM; Van Der Kraak G; Wade MG; Willett CE; Andersen ME; Borgert CJ; Coady KK; Dourson ML; Fowle JR; Gray LE; Lamb JC; Ortego LS; Schug TT; Toole CM; Zorrilla LM; Kroner OL; Patterson J; Rinckel LA; Jones BR
ALTEX; 2014; 31(1):63-78. PubMed ID: 24114257
[TBL] [Abstract][Full Text] [Related]
11. Development, validation and integration of in silico models to identify androgen active chemicals.
Manganelli S; Roncaglioni A; Mansouri K; Judson RS; Benfenati E; Manganaro A; Ruiz P
Chemosphere; 2019 Apr; 220():204-215. PubMed ID: 30584954
[TBL] [Abstract][Full Text] [Related]
12. Assessment of in vivo assays for endocrine disruption.
Clode SA
Best Pract Res Clin Endocrinol Metab; 2006 Mar; 20(1):35-43. PubMed ID: 16522518
[TBL] [Abstract][Full Text] [Related]
13. Application of an integrated testing strategy to the U.S. EPA endocrine disruptor screening program.
Willett CE; Bishop PL; Sullivan KM
Toxicol Sci; 2011 Sep; 123(1):15-25. PubMed ID: 21642633
[TBL] [Abstract][Full Text] [Related]
14. Screening chemicals for thyroid-disrupting activity: A critical comparison of mammalian and amphibian models.
Pickford DB
Crit Rev Toxicol; 2010 Nov; 40(10):845-92. PubMed ID: 20684730
[TBL] [Abstract][Full Text] [Related]
15. Application of Adverse Outcome Pathways to U.S. EPA's Endocrine Disruptor Screening Program.
Browne P; Noyes PD; Casey WM; Dix DJ
Environ Health Perspect; 2017 Sep; 125(9):096001. PubMed ID: 28934726
[TBL] [Abstract][Full Text] [Related]
16. Key learnings from the Endocrine Disruptor Screening Program (EDSP) Tier 1 rodent uterotrophic and Hershberger assays.
Marty MS; O'Connor JC
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):63-79. PubMed ID: 24515841
[TBL] [Abstract][Full Text] [Related]
17. Hypothesis-driven weight of evidence evaluation indicates styrene lacks endocrine disruption potential.
Borgert CJ
Crit Rev Toxicol; 2023 Feb; 53(2):53-68. PubMed ID: 37216681
[TBL] [Abstract][Full Text] [Related]
18. Cross-species conservation of endocrine pathways: a critical analysis of tier 1 fish and rat screening assays with 12 model chemicals.
Ankley GT; Gray LE
Environ Toxicol Chem; 2013 Apr; 32(5):1084-7. PubMed ID: 23401061
[TBL] [Abstract][Full Text] [Related]
19. Xenoendocrine disrupters-tiered screening and testing: filling key data gaps.
Gray LE; Ostby J; Wilson V; Lambright C; Bobseine K; Hartig P; Hotchkiss A; Wolf C; Furr J; Price M; Parks L; Cooper RL; Stoker TE; Laws SC; Degitz SJ; Jensen KM; Kahl MD; Korte JJ; Makynen EA; Tietge JE; Ankley GT
Toxicology; 2002 Dec; 181-182():371-82. PubMed ID: 12505339
[TBL] [Abstract][Full Text] [Related]
20. Use of the laboratory rat as a model in endocrine disruptor screening and testing.
Gray LE; Wilson V; Noriega N; Lambright C; Furr J; Stoker TE; Laws SC; Goldman J; Cooper RL; Foster PM
ILAR J; 2004; 45(4):425-37. PubMed ID: 15454681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]